Palatin to Start Clinical Trials of Ulcerative Colitis Therapy After FDA Sign-off

Palatin to Start Clinical Trials of Ulcerative Colitis Therapy After FDA Sign-off
Palatin Technologies plans to start clinical trials of its ulcerative colitis therapy PL-8177 in the next three months. The U.S. Food and Drug Administration’s decision to accept Palatin’s Investigational New Drug application for the treatment opened the door to the trials. PL-8177 regulates a protein known as melanocortin receptor 1, which plays a role in inflammation and immune system response. A

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *